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e under theAbstract Background: Jordan lacks statistical data regarding prevalence of HCV.
Aim: To determine the prevalence of HCV in selected areas of Jordan (north,
middle and south of Jordan).
Methods: A random sample of 700 patients attending health centers was used to
determine HCV prevalence. ELISA testing was used to determine HCV-Ab positive
cases, which were confirmed by PCR testing.
Results and conclusion: The study concluded that the prevalence of HCV infection
in the population recruited from different health centers in Jordan is relatively low
and estimates a prevalence of 0.42% among all age groups and 0.56% among those
aged >15 years old.
ª 2013 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/Within the EMR, there is a lack of accurate statisti-
by-nc-nd/4.0/).1. Introduction
Infection with hepatitis C virus (HCV) is a major
cause of chronic liver disease. Worldwide there
are more than 170 million people infected with
HCV, and 4 million people are newly infected each
year [1,2].
The World Health Organization (WHO) has pro-
r six regions, includ-
3 Ministry of Health, Saudi Ar
3.02.003
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yahoo.com (W. Hamoudi).
CC BY-NC-ND license (http://ing the Eastern Mediterranean Region (EMR)1 which
includes 22 countries in North Africa, the Middle
East and South Asia. WHO estimates that the num-
ber of HCV-infected individuals in the EMR is about
21 million [1], however, there have been a few
prevalence studies carried out at the national or
regional level that could corroborate this value.abia. Published by Elsevier Ltd.
1 TheWHO Eastern Mediterranean Region comprises 22 Member
States: Afghanistan, Bahrain, Djibouti, Egypt, Islamic Republic of
Iran, Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya,
Morocco, Oman, Pakistan, Qatar, Saudi Arabia, Somalia, South
Sudan, Sudan, Syrian Arab Republic, Tunisia, United Arab
Emirates, Yemen, as well as the occupied Palestinian territory.
creativecommons.org/licenses/by-nc-nd/4.0/).
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in numerous countries, including Jordan. The
objective of this study was to try to determine
the magnitude of HCV infection in Jordan and to
describe the demographic and disease characteris-
tics of those infected by HCV.
2. Background
WHO estimates a worldwide anti-HCV prevalence
of 3% [3]. In combination with hepatitis B, chronic
HCV infection accounts for 75% of all cases of liver
disease [3]. In developing countries, chronic hepa-
titis C is a leading cause of liver cirrhosis, hepato-
cellular carcinoma and liver transplantation.
Historically, transmission of HCV in the develop-
ing world has been largely iatrogenic. Today, spo-
radic transmission is more prevalent (drug
addicts, needle sharing, needle-stick injury in med-
ical personnel, tattooing and piercing or razor shar-
ing) [4].
In 1999, WHO estimated that 21.3 million of the
466 million people in the EMR were infected by
HCV, resulting in an anti-HCV prevalence rate of
4.6% [1]. The same report provided an estimated
seroprevalence rate of 2.1% for Jordan based upon
previously published regional estimates. Within the
EMR, the highest rates of anti-HCV have been re-
ported in Egypt (14.5%) and Pakistan (3–4.7%)
[5–7].
The Jordanian National Strategy for Hepatitis B
& C formulated several recommendations aimed
at improved understanding and control of viral hep-
atitis within Jordan. One such recommendation
was to conduct a nationwide epidemiological study
regarding the prevalence of HCV in Jordan [8]. In
accordance with this recommendation, the primary
objective of this study was to determine the prev-
alence of HCV in selected areas in Jordan (north,
middle and south of Jordan) and to identify risk
factors for HCV infection among Jordanian
citizens.
There have been relatively few studies quantify-
ing the burden of HCV infection for Jordan. In one
study, the estimated anti-HCV prevalence rate
among the general population was estimated at
1.2% [9]. In another study, prevalence rates among
several sub-populations at two hospitals in the
Amman region were examined; hospital employees
had an anti-HCV prevalence of 0.65% while hemod-
ialysis (HD) patients had an anti-HCV prevalence of
6.25%; prevalence rates were found to be higher
among older age groups [9]. A 2009 study reported
anti-HCV antibodies of 28% among long-term HD
patients in southern Jordan [10]. In a study of pa-tients with hereditary hemolytic anemia, 40.5%
were anti-HCV positive, with anemia diagnosis
prior to 1995 (when blood screening began) predic-
tive of anti-HCV positivity [11]. The predominant
genotype for HD patients was 1a [12].
Nations near Jordan have conducted studies to
quantify and describe the national burden of HCV.
In Lebanon, a study of 16,000 blood donors found
a seroprevalence of 0.404% and a decline in preva-
lence from 1.22% to 0.16% between 1997 and 2003
[13]. An earlier study found a seroprevalence rate
of 0.41% among 7,771 blood donors and 27% in HD
patients with length of time on HD predictive of
HCV seropositivity [14]. A study of injection drug
users (IDU) in Lebanon found that 52.8% were
anti-HCV positive [15]. A study of male Lebanese
prisoners found an anti-HCV prevalence of 3.4%
and identified risk factors including IDU, previous
imprisonment and tattooing [16]. The predominant
genotypes in Lebanon were genotypes 4 and 1a [17].
Anti-HCV prevalence in Saudi Arabia shows varia-
tion with estimates ranging from 0.6% to 1.1%
among blood donors [18–20].Studies of HD patients
show varied prevalence rates (14.7% to 68%), but
nosocomial transmission before blood screening is
probably a large contributor to prevalence in Saudi
Arabia [21]. A study of sera from over 3,000 patients
at a large medical center in Saudi Arabia showed
that anti-HCV prevalence varied between age
groups from 2.05% in ages 15-24 up to 15% for those
aged 45-54 [22]. A community-based study in Saudi
Arabia showed that 14.8% of anti-HCV-positive indi-
viduals reported a history of blood transfusion and
7.4% reported a history of schistosomiasis [23].
Anti-HCV prevalence among several groups in
Syria has been measured, including blood donors
(0.95%), sex workers (1.96%), health care workers
(3%), injection drug users (IDU) (60.5%), and HD pa-
tients (48.9%) [24–26]. In Iraq, a study of nearly
500,000 blood donors in Baghdad between 2006
and 2009 demonstrated anti-HCV prevalence of
0.3% with higher prevalence among women (0.4%)
as compared with men (0.2%) [27]. A study of 169
HD patients in Baghdad showed an anti-HCV preva-
lence of 7.1%, with female gender, older age, dura-
tion of HD, and history of blood transfusion as risk
factors [28–30].
3. Methods
Three main populated areas in Jordan were se-
lected to investigate random visitors of the com-
prehensive health centers for issues other than
liver disease to estimate anti-HCV prevalence in
those areas. The sample size was estimated using
Table 1 Distribution of study sample by region.
Region Population
(thousands)
Percentage Proposed No. of
participants
No. Participants
Irbid 1087 29 206 201
Amman 2369 64 449 404
Karak 241 7 46 101
Total 3697 700 706
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and Prevention, Atlanta, GA). Based on the esti-
mated prevalence in Jordan being 1-2% [9] and a
95% confidence level, the required sample size
was calculated to include 380 people. To increase
the power of the study, the sample size was in-
creased to 706 people. Study populations were se-
lected proportional to population size from three
regions which represent Jordan: north (Irbid), cen-
tral (Amman) and south (Karak). A random selec-
tion of patients attending selected comprehensive
health centers for other diseases was performed;
urban and rural areas, age groups and gender were
considered.
To ensure representativeness, study populations
were selected proportional to population size from
all three regions. In addition, age groups were se-
lected proportional to the percentage of the age
groups in the general population as illustrated in
Table 1.
3.1. Selection criteria
Two health centers were selected from south
Jordan, three from north Jordan and four from
central Jordan. For each participant, a short inves-
tigation form assessing demographics and risk fac-
tor exposures was completed by co-investigators
under the supervision of the investigators.
Five milliliters of venous blood was collected by
trained laboratory technicians in a plain tube with
gel; blood specimens were centrifuged and trans-
ported to the referral lab refrigerated in an ice
box for HCV-Ab testing by ELISA. Antibodies to
HCV were detected using the ELISA 192 Test DIA
pro system (cat # CVAB.CE) Anti-HCV V 4.0. ELISA
(DIAsource ImmunoAssays (BioSource), Belgium).Table 2 Distribution of participants by area of residence and
Age_Group Irbid Amman Kar
<5 23 24 6
5–14 49 72 21
P15 129 308 74
Total 201 404 101All persons with positive HCV-Ab by ELISA were pro-
vided confirmatory testing by PCR – Abbott Real-
time HCV quantitative assay (Abbott Laboratories,
Rungis, France), with a detection limit of 10 IU/
ml and tested for genotype .The HCV genotype
was determined by sequence analysis using the
HCV genotyping Trugene assay (Bayer, Puteaux,
France) and referred to the hepatologist for appro-
priate clinical care.
The number of participants from Karak was in-
creased to 100 due to the relatively small popula-
tion in this region.
3.2. Exclusion criteria
Non-Jordanian citizens were excluded from this
study.
3.3. Ethical issues
Data collected were treated confidentially, and all
participants provided informed consent for this
study. Serum collection tubes were identified by
random identification numbers and the specimens
were sent to the laboratory with a list of identifica-
tion without the names of participants. This study
was approved by the Ministry of Health Ethics Com-
mittee (MOH/EC/13700/2011).
3.4. Statistical assessment
Seroprevalence was calculated for the study group
and by region, sex, and age group. Significant
associations were determined using Pearsons
chi-square test, or, when small sample sizes neces-
sitated, Fishers exact test. P values <0.05 were
considered significant.age group.
ak Total Proportion by age groups
53 7.5
142 20.1
511 72.4
706 100.0
Table 3 Age specific prevalence rate of HCV-Ab.
Age_Group Positive HCV Ab Negative HCV Ab Total Prevalence Rate per 1000
<5 0 53 53 0.0
5–14 0 142 142 0.0
P15 3 508 511 5.9
Total 3 703 706 4.2
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A total number of 706 persons met eligibility
requirements and were selected for testing for
anti-HCV antibodies (HCV-Ab) by ELISA test from
the three selected areas. They were further strat-
ified by age groups and area of residence as illus-
trated in Table 2.
The prevalence of HCV-Ab among the study pop-
ulation was 4.2 per thousand (0.42%). All HCV-Ab
positive patients were from the P15 age group;
taking into consideration that the worldwide prev-
alence is very low among those less than 15 years
old, the age specific prevalence rate among the
P15 age group was 5.9 per thousand (0.59%) as
illustrated in Table 3.
All persons with positive HCV-Ab by ELISA were
provided confirmatory testing by PCR and testing
for genotype, which showed that all infected per-
sons were infected with HCV genotype 4.5. Discussion
This is the first multi-region study assessing sero-
prevalence of HCV in Jordan. The results of this
study reiterate results from previous studies within
Jordan and some nearby countries that demon-
strate a relatively low burden of HCV infection as
compared with other nations within the EMR.
This study was subject to several limitations.
First, participants recruited at health centers may
not be representative of Jordanian citizens at the
national level. The prevalence of HCV is lower than
that reported through earlier studies in Jordan and
some neighboring countries. However, the preva-
lence reported among blood donors in Lebanon
(0.40%) was relatively low and showed a decline
over time from 1.22% to 0.16% between 1997 and
2003 [13].
In conclusion, this study assesses the seropreva-
lence of HCV in Jordan among participants from
three geographical regions. It confirms that the
prevalence of HCV in Jordan is low, 0.42% among
all age groups, and 0.56% among age groups >15
years old. There is a need for better understandingof HCV infection in Jordan and other developing
countries, as well as stronger efforts to mitigate
transmission of HCV.
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